Tag: Calithera Biosciences
March 26, 2019
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences (NASDAQ:CALA) has announced the first patietn has been treated in its Phase 1/2 open-label clinical trial of the...
October 21, 2018
5 Top Weekly NASDAQ Biotech Stocks: MannKind Leads the Pack
MannKind, Sierra Oncology, Eiger BioPharmaceuticals, Aevi Genomic Medicine and KalVista Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology... October 5, 2018
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced two new... April 18, 2018
Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839
Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the... March 9, 2018
Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights
Calithera Biosciences (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism...
April 19, 2017